Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-dfsvx Total loading time: 0 Render date: 2024-04-27T04:25:52.144Z Has data issue: false hasContentIssue false

Chapter 2 - Psychiatric Drug Discovery and Development

from Part 1 - Basic Science and General Principles

Published online by Cambridge University Press:  29 May 2020

By
Mohammed Shahid ,
Joanna C. Neill  and
John Hutchison
Edited by
Peter M. Haddad  and
David J. Nutt
Peter M. Haddad
Affiliation:
Hamad Medical Corporation, Qatar
David J. Nutt
Affiliation:
Centre for Neuropsychopharmacology, Division of Psychiatry, Department of Brain Sciences, Imperial College London
Get access

Summary

This chapter reviews the process of psychiatric drug discovery and development. People suffering from mental illness need better drugs with improved efficacy and reduced side-effect burden than those currently available. The aim of drug discovery and development in this area is to manage illness, improve quality of life, and to reduce burden on carers and on the economy. Long-term disability associated with incomplete treatment response profoundly compromises the ability of affected individuals to function properly and significantly reduces their quality of life. This in turn has societal consequences in terms of the cost burden associated with the high prevalence of psychiatric disorders. Brain disorders cost €141 billion per annum in the UK, with a total 2010 cost (in million € purchasing power parity) of psychotic disorders of €16 717 (Fineberg et al., 2013).

Type
Chapter
Information
Seminars in Clinical Psychopharmacology , pp. 35 - 68
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ayhan, Y, Pletnikov, M (2016). Contributions to understanding the causes and treatment of schizophrenia. In Abel, T, Nickl-Jockshatt, T, eds., The Neurobiology of Schizophrenia 1. Cambridge, MA: Academic Press.Google Scholar
Bale, TL, Epperson, CN (2017). Sex as a biological variable: who, what, when, why, and how. Neuropsychopharmacology, 42, 386–396.Google Scholar
Banzi, R, Geraldi, C, Bertele, V, Garattini, S (2017). Conditional approval of medicines by EMA. BMJ, 357, j2062.Google Scholar
Barnes, SA, Sawiak, SJ, Caprioli, D, et al. (2014). Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia. Int J Neuropsychopharmacol, 18(2), 1–12.Google Scholar
Baroni, A, Castellanos, FX (2015). Stimulants, cognition and ADHD. Curr Opin Behav Sci, 4, 109–114.Google Scholar
Belzung, C, Lemoine, M (2011). Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol Mood Anxiety Disord, 1(1), 9.CrossRefGoogle ScholarPubMed
Bespalov, A, Steckler, T, Altevogt, B, et al. (2016). Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets. Nat Rev Drug Discov, 15, 516.Google Scholar
Bhakta, SG, Young, JW (2017). The 5 choice continuous performance test (5C-CPT): a novel tool to assess cognitive control across species. J Neurosci Methods, 292, 53–60.Google Scholar
Birnbaum, R, Weinberger, DR (2017). Genetic insights into the neurodevelopmental origins of schizophrenia. Nature Rev Neuorsci, 18: 727–740. doi:10.1038/nrn.2017.125.Google Scholar
Bishop, KM (2017). Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases. Neuropharmacology, 120, 56–62.Google Scholar
Borsook, D, Becerra, L, Fava, M (2013). Use of functional imaging across clinical phases in CNS drug development. Transl Psychiatry, 3(7), e282. doi:10.1038/tp.2013.43.CrossRefGoogle ScholarPubMed
Buchanan, RW, Panagides, J, Zhao, J, et al. (2012). Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol, 32, 36–45.CrossRefGoogle ScholarPubMed
Bugarski-Kirola, D, Blaettler, T, Arango, C, et al. (2017). Bitopertin in negative symptoms of schizophrenia – results from the phase III FlashLyte and DayLyte studies. Biol Psychiatry, 82, 8–16.CrossRefGoogle ScholarPubMed
Cacabelos, R, Torrellas, C, Fernández-Novoa, L, López-Muñoz, F (2016). Histamine and immune biomarkers in CNS disorders. Mediators Inflamm, 2016, 1924603. doi:10.1155/2016/1924603.Google Scholar
Cadinu, D, Grayson, B, Podda, G, et al. (2018). NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology, 142, 41–62. doi:10.1016/j.neuropharm.2017.11.045.CrossRefGoogle ScholarPubMed
Cahill, L (2014). Equal not equal the same: sex differences in the human brain. Cerebrum, 2014, 5.Google Scholar
Caron, J, Rochoy, M, Gaboriau, L, Gautier, S (2016). The history of pharmacovigilance. Thérapie, 71, 129–134.Google Scholar
Catafau, AM, Bullich, S (2013). Molecular imaging PET and SPECT approaches for improving productivity of antipsychotic drug discovery and development. Curr Med Chem, 20(3), 378–388.Google Scholar
Chandra, S, Siraj, S, Wong, DKY (2017). Recent advances in biosensing for neurotransmitters and disease biomarkers using microelectrodes. ChemElectroChem, 4, 822–833. doi:10.1002/celc.201600810.Google Scholar
Chaudhry, IB, Husain, N, ur Rahman, R, et al. (2015). A randomised double-blind placebo-controlled 12-week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial. Trials, 16, 9.CrossRefGoogle Scholar
Chen, X, Broeyer, F, de Kam, M, et al. (2017). Pharmacodynamic response profiles of anxiolytic and sedative drugs. Br J Clin Pharmacol, 83(5), 1028–1038.Google Scholar
Choudhury, SR, Hudry, E, Maguire, CA, et al. (2017). Viral vectors for therapy of neurologic diseases. Neuropharmacology, 120, 63–80.CrossRefGoogle ScholarPubMed
Clayton, JA (2017). Studying both sexes: a guiding principle for biomedicine. FASEB J, 30(2), 519–524.Google Scholar
Clayton, JA, Collins, FS (2014). Policy: NIH to balance sex in cell and animal studies. Nature, 509, 282–283.CrossRefGoogle ScholarPubMed
Clementz, BA, Sweeney, JA, Hamm, JP, et al. (2016). Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry, 173, 373–384.Google Scholar
Cook, D, Brown, D, Alexander, R, et al. (2014). Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov, 13, 419–431.Google Scholar
Cuthbert, BN (2015). Research domain criteria: toward future psychiatric nosologies. Dialogues Clin Neurosci, 17(1), 89–97.Google Scholar
Dolgin, E (2014). Drug discoverers chart path to tackling data irreproducibility. Nat Rev Drug Discov, 13(12), 875–876.Google Scholar
Dolgos, H, Trusheim, M, Gross, D, et al. (2016). Translational Medicine Guide transforms drug development processes: the recent Merck experience. Drug Discov Today, 21, 517–526.Google Scholar
Downing, AM, Kinon, BJ, Millen, BA, et al. (2014). A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry, 14, 351–363.Google Scholar
Doyle, OM, De Simoni, S, Schwarz, AJ, et al. (2013). Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents. J Pharmacol Exp Ther, 354(1), 151–160.CrossRefGoogle Scholar
Erickson, MA, Ruffle, A, Gold, JM (2016). A meta-analysis of mismatch negativity in schizophrenia: from clinical risk to disease specificity and progression. Biol Psychiatry, 79(12), 980–987.Google Scholar
European Medicines Agency (2014). EMA/CHMP/539931/2014. Draft guidance on the clinical investigation of medicines for the treatment of Alzheimer’s disease and other dementias.Google Scholar
European Medicines Agency (2016). EMA/CHMP/458101/2016. Guideline on the qualification and reporting of physiologically based pharmacokinetic modelling and simulation: consultation document.Google Scholar
European Medicines Agency (2018). EMEA/CHMP/SWP/28367/07 Rev 1. Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products.Google Scholar
Evans, BJ (2012). The ethics of postmarketing observational studies of drug safety under section 505(o)(3) of the Food, Drug, and Cosmetic Act. Am J Law Med, 38(4), 577–606.CrossRefGoogle Scholar
FDA (2005a). Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers: Guidance for Industry. Center for Drug Evaluation and Research (CDER). Available at: www.fda.gov/drugs/guidances-drugs/all-guidances-drugs (last accessed 19.8.19).Google Scholar
FDA (2005b). Development and Use of Risk Minimization Action Plans: Guidance for Industry. Available at: www.fda.gov/drugs/guidances-drugs/all-guidances-drugs (last accessed 19.8.19).Google Scholar
FDA (2018). Physiologically Based Pharmacokinetic Analyses – Format and Content: Guidance for Industry. Center for Drug Evaluation and Research (CDER). Available at: www.fda.gov/drugs/guidances-drugs/all-guidances-drugs (last accessed 19.8.19).Google Scholar
Fineberg, NA, Haddad, PM, Carpenter, L, et al. (2013). The size, burden and cost of the brain in the UK. J Psychopharmacol, 27(9), 761–770.Google Scholar
Finnema, S, Eid, T, Dhaher, R, et al. (2016). 11C-UCB-J as a biomarker for synaptic density – an in vivo/in vitro validation study. J Nucl Med, 57(Suppl 2), 1800.Google Scholar
Foley, C, Corvin, A, Nakagome, S (2017). Genetics of schizophrenia: ready to translate? Curr Psychiatry Rep, 19(9), 61.Google Scholar
Fosgerau, K, Hoffmann, T (2015). Peptide therapeutics: current status and future directions. Drug Discov Today, 20, 122–128.Google Scholar
French, JA, Krauss, GL, Kasteleijn, D, DiVentura, BD, Bagiella, E (2014). Effects of marketed antiepileptic drugs and placebo in the human photosensitivity screening protocol. Neurotherapeutics, 11(2), 412–418.CrossRefGoogle ScholarPubMed
Freskgård, PO, Urich, E (2017). Antibody therapies in CNS diseases. Neuropharmacology, 120, 38–55.Google Scholar
Frye, SV, Arkin, MR, Arrowsmith, CH, et al. (2015). Tackling reproducibility in academic preclinical drug discovery. Nat Rev Drug Discov, 14(11), 733–734.CrossRefGoogle ScholarPubMed
Garden, GA, Campbell, BM (2016). Glial biomarkers in human central nervous system disease. Glia, 64(10), 1755–1771.Google Scholar
Gashaw, I, Ellinghaus, P, Sommer, A, Asadullah, K (2012). What makes a good drug target? Drug Discov Today, 17 Suppl, S24–S30.CrossRefGoogle ScholarPubMed
Geerts, H, Spiros, A, Roberts, P (2017). Phosphodiesterase 10 inhibitors in clinical development for CNS disorders. Expert Rev Neurother, 17, 553–560.CrossRefGoogle ScholarPubMed
Girgis, RR, Ciarleglio, A, Choo, T, et al. (2018). Randomized double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology, 43, 1317–1323.Google Scholar
Goetghebeur, PJD, Dias, R (2014). The attentional set-shifting test paradigm in rats for the screening of novel pro-cognitive compounds with relevance for cognitive deficits in schizophrenia. Curr Pharm Des, 20, 5060–5068.Google Scholar
Grabowski, HG, Hansen, RW (2014). Costs of developing a new drug. Tufts Center for the Study of Drug Development. Available at: http://csdd.tufts.edu (last accessed 20.10.19).Google Scholar
Grünberger, J, Saletu, B, Linzmayer, L, Stöhr, H (1985). Determination of pharmacokinetics and pharmacodynamics of amisulpride by pharmaco-EEG and psychometry. In Pichot, P, Berner, P, Wolf, R, Thau, K, eds., Psychiatry the State of the Art. Boston, MA: Springer, pp. 681–686.Google Scholar
Harrison, RK (2016). Phase II and phase III failures: 2013–2015. Nat Rev Drug Discov, 15, 817–818.Google Scholar
Heekeren, K, Daumann, J, Neukirch, A, et al. (2008). Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl), 199, 77–88.Google Scholar
Hendrie, C, Pickles, A (2013). The failure of the antidepressant drug discovery process is systemic. J Psychopharmacol, 27(5), 407–416.Google Scholar
Herrero, JF, Laird, JM, López-García, JA (2000). Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog Neurobiol, 61(2), 169–203.Google Scholar
Herrmann, WM, Fichte, K, Itil, TM, Kubicki, ST (1979). Acute efficacy of 20 psychotropic drugs on human EEG power spectrum variables shown by multivariate and univariate statistics. In Saletu, B, Berner, P, Hollister, L, eds., Neuropsychopharmacology: Proceedings of the 11th Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Vienna 1978. Oxford: Pergamon Press, pp. 371–382.Google Scholar
Hutson, PH, Clark, JA, Cross, AJ (2017). CNS target identification and validation: avoiding the valley of death or naive optimism? Ann Rev Pharmacol Toxicol, 57, 171–187.Google Scholar
Insel, T, Cuthbert, B, Garvey, M, et al. (2010). Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry, 167(7), 748–751.Google Scholar
Jentsch, JD, Roth, RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 20, 201–225.Google Scholar
Jones, HM, Rowland-Yo, K (2013). Basic concepts in PBPK modelling in drug discovery and development. Pharmacometrics Syst Pharmacol, 2, e63.Google Scholar
Jones, HM, Mayawala, K, Poulin, P (2013). Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. AAPS J, 15(2), 377–387.Google Scholar
Kas, MJ, Penninx, B, Sommer, B, et al. (2019). A quantitative approach to neuropsychiatry: the why and the how. Neurosci Biobehav Rev, 97, 3–9.Google Scholar
Keefe, RS, Bilder, RM, Davis, SM, et al.; CATIE Investigators; Neurocognitive Working Group (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry, 64(6), 633–647.Google Scholar
Keshavan, MS, Lawler, AN, Nasrallah, HA, Tandon, R (2017). New drug developments in psychosis: challenges, opportunities and strategies. Prog Neurobiol, 152, 3–20.Google Scholar
Kesselheim, AS (2010). Innovation and the Orphan Drug Act,1983–2009: regulatory and clinical characteristics of approved orphan drugs. In Field, MJ, Boat, TF, eds., Rare Disease and Orphan Products: Accelerating Research and Development. Washington, DC: National Academies Press, Appendix B.Google Scholar
Khoury, C, Duque, R, Freiberg, M (2015). Trial design and market access implications: outcomes from comparator choice. Value Health, 18(7), A723.Google Scholar
Kola, I (2008). The state of innovation in drug development. Clin Pharmacol Ther, 83, 227–230.Google Scholar
Kothur, K, Wienholt, L, Brilot, F, Dale, RC (2016). CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review. Cytokine, 77, 227–237.CrossRefGoogle ScholarPubMed
Knuesel, I, Chicha, L, Britschgi, M, et al. (2014). Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol, 10, 643–660.CrossRefGoogle ScholarPubMed
Leger, M, Neill, JC (2016). A systematic review comparing sex differences in cognitive function in schizophrenia and in rodent models for schizophrenia, implications for improved therapeutic strategies. Neurosci Biobehav Rev, 68, 979–1000.CrossRefGoogle ScholarPubMed
Leger, M, Alvaro, G, Large, C, Harte, MK, Neill, JC (2015). AUT6, a novel Kv3 channel modulator, reverses cognitive and neurobiological dysfunction in a rat model of relevance to schizophrenia symptomatology. Eur Neuropsychopharmacol, 25, S480.CrossRefGoogle Scholar
Marder, SR (2006). The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci, 8(1), 109–113.Google Scholar
Marsh, S (2015). Investigation of the neuronal marker N-acetylaspartate as a potential biomarker for neurological diseases. Unpublished PhD thesis, University of Manchester.Google Scholar
Marson, FAL, Bertuzzo, CS, Ribeiro, JD (2017). Personalized or precision medicine? The example of cystic fibrosis. Front Pharmacol, 8, 390.Google Scholar
Matthews, H, Hanison, J, Nirmalan, N (2016). ‘Omics’-informed drug and biomarker discovery: opportunities, challenges and future perspectives. Proteomes, 4(3), 28.Google Scholar
Matthews, PM, Rabiner, EA, Passchier, J, Gunn, RN (2012). Positron emission tomography molecular imaging for drug development. Br J Clin Pharmacol, 73(2), 175–186.Google Scholar
Millan, MJ, Goodwin, GM, Meyer-Lindenberg, A, Ove Ögren, S (2015). Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders. Eur Neuropsychopharmacol, 25(5), 599–656.Google Scholar
Möller, HJ, Czobor, P (2015). Pharmacological treatment of negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci, 265, 567–578.Google Scholar
Moran, PM (2016). Behavioral phenotypes of genetic models: contributions to understanding the causes and treatment of schizophrenia. In Abel, T, Nickl-Jockshatt, T, eds., The Neurobiology of Schizophrenia 1. Cambridge, MA: Academic Press, pp. 383–396.Google Scholar
Morgan, P, Van Der Graaf, PH, Arrowsmith, J, et al. (2012). Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today, 17, 419–424.Google Scholar
Munafò, M, Neill, JC (2016). Null is beautiful: on the importance of publishing null results. J Psychopharmacol, 30(7), 585.Google Scholar
Neill, JC, Kulkarni, J (eds.) (2011). Biological basis of sex differences in psychopharmacology. Current Topics in Behavioral Neurosciences, Vol. 8 (series editors: Marsden, C, Ellenbroek, B, Geyer, M). Heidelberg: Springer-Verlag, pp. v–vii.Google Scholar
Neill, JC, Barnes, S, Cook, S, et al. (2010). Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther, 128(3), 419–432.Google Scholar
Neill, JC, Harte, MK, Haddad, PM, Lydall, ES, Dwyer, DM (2014). Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans. Eur Neuropsychopharmacol, 24, 822–835.Google Scholar
Németh, B, Laszlovsky, I, Czobor, P, et al. (2017). Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet, 389(10074), 1103–1113. doi:10.1016/S0140-6736(17)30060-0.Google Scholar
Newhouse, PA, Conley, AC, Key, AP (2017). Exploring novel cognitive and electrophysiological markers of target engagement in Phase 1 and 2 studies of putative cholinergic cognitive enhancers. Alzheimers Dement, 13(7), P1255–P1256. https://doi.org/10.1016/J.JALZ.2017.06.1870.Google Scholar
Nielsch, U, Fuhrmann, U, Jaroch, S (2016). New approaches to drug discovery. Handb Exp Pharmacol, 232, v–vi.Google Scholar
Nutt, DJ, Stahl, S, Blier, B, et al. (2017). Inverse agonists – what do they mean for psychiatry? Eur Neuropsychopharmacol, 27(1), 87–90. http://dx.doi.org/10.1016/j.euroneuro.2016.11.013.Google Scholar
Olesen, AE, Andresen, T, Staahl, C, Drewes, AM (2012). Human experimental pain models for assessing the therapeutic efficacy of analgesic drugs. Pharmacol Rev, 64(3), 722–779.Google Scholar
Pak, C, Danko, T, Zhang, Y, et al. (2015). Human neuropsychiatric disease modeling using conditional deletion reveals synaptic transmission defects caused by heterozygous mutations in NRXN1. Cell Stem Cell, 17(3), 316–328.CrossRefGoogle ScholarPubMed
Picton, TW (1992). The P300 wave of the human event-related potential. J Clin Neurophysiol, 9(4), 456–479.Google Scholar
Plosker, GL, Deeks, ED (2016). Asenapine: a review in schizophrenia. CNS Drugs, 30(7), 655–666.Google Scholar
Pompili, M, Verzura, C, Trovini, G, et al. (2017). Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders. Expert Opin Drug Saf, 26, 1–9.Google Scholar
Potkin, SG, Cohen, M, Panagides, J (2007). Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry, 68(10), 1492–1500.CrossRefGoogle ScholarPubMed
Potkin, SG, Phiri, P, Szegedi, A, et al. (2013). Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis. Schizophr Res, 150, 442–449.Google Scholar
Pringle, A, Harmer, CJ (2015). The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment. Dialogues Clin Neurosci, 17(4), 477–487.Google Scholar
Prinz, F, Schlange, T, Asadullah, K (2011). Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov, 10(9), 712.Google Scholar
Rao, P, Benito, E, Fischer, A (2013). MicroRNAs as biomarkers for CNS disease. Front Mol Neurosci, 26(6), 39.Google Scholar
Rekowski, J, Köllmann, C, Bornkamp, B, Ickstadt, K, Scherag, A (2017). Phase II dose-response trials: a simulation study to compare analysis method performance under design considerations. J Biopharm Stat, 21, 1–17.Google Scholar
Reynolds, GP, Neill, JC (2016). Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine. J Psychopharmacol, 30(11), 1141–1144.Google Scholar
Sahli, ZT, Tarazi, FI (2018). Pimavanserin: novel pharmacotherapy for Parkinson’s disease psychosis. Expert Opin Drug Discov, 13(1), 103–110.Google Scholar
Sanacora, G, Frye, MA, McDonald, W, et al.; American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017). A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 74, 399–405.Google Scholar
Sanchez, C, Asin, KE, Artigas, F (2015). Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther, 145, 43–57.Google Scholar
Scarff, JR (2017). The prospects of cariprazine in the treatment of schizophrenia. Ther Adv Psychopharmacol, 7(11), 237–239.Google Scholar
Schizophrenia Working Group of the Psychiatric Genomics C (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511(7510), 421–427.Google Scholar
Schmidt, R (1988). Dose-finding studies in clinical drug development. Eur J Clin Pharmacol, 34(1), 15–19.Google Scholar
Seshadri, M, Banerjee, D, Viswanath, B, et al. (2017). Cellular models to study schizophrenia: a systematic review. Asian J Psychiatr, 25, 46–53.Google Scholar
Shahid, M, Walker, GB, Zorn, SH, Wong, EH (2009). Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol, 23(1), 65–73.Google Scholar
Shannon, RJ, Carpenter, KLH, Guilfoyle, MR, Helmy, A, Hutchinson, PJ (2013). Cerebral microdialysis in clinical studies of drugs: pharmacokinetic applications. J Pharmacokinet Pharmacodyn, 40(3), 343–358.Google Scholar
Singh, I, Morgan, C, Curran, V, et al. (2017). Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. Lancet Psychiatry, 4, 419–426.Google Scholar
Sirven, JI (2010). New uses for older drugs: the tales of aspirin, thalidomide, and gabapentin. Mayo Clin Proc, 85(6), 508–511.Google Scholar
Snyder, PJ, Bednar, MM, Cromer, JR, Maruff, P (2005). Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimers Dement, 1(2), 126–135.Google Scholar
Soliman, MA, Aboharb, F, Zeltner, N, Studer, L (2017). Pluripotent stem cells in neuropsychiatric disorders. Mol Psychiatry, 22(9), 1241–1249.CrossRefGoogle ScholarPubMed
Staahl, C, Drewes, AM (2004). Experimental human pain models: a review of standardised methods for preclinical testing of analgesics. Basic Clin Pharmacol Toxicol, 95(3), 97–111.Google Scholar
Suntharalingam, G, Perry, MR, Ward, S, et al. (2006). Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med, 355, 1018–1028.Google Scholar
Takano, A (2010). The application of PET technique for the development and evaluation of novel antipsychotics. Curr Pharm Des, 16(3), 371–377.Google Scholar
Talpos, JC (2017). Symptomatic thinking: the current state of Phase III and IV clinical trials for cognition in schizophrenia. Drug Discov Today, 22, 1017–1026.Google Scholar
Tarazi, FI, Neill, JC (2013). The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania. Expert Opin Drug Discov, 8(1), 93–103.Google Scholar
Tarazi, FI, Shahid, M (2009). Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania. Drugs Today (Barc), 45, 865–876.Google Scholar
Turner, MA, Catapano, M, Hirschfeld, S, Giaquinto, C; Global Research in Paediatrics (2014). Paediatric drug development: the impact of evolving regulations. Adv Drug Deliv Rev, 73, 2–13.Google Scholar
Waring, MJ, Arrowsmith, J, Leach, AR, et al. (2015). An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov, 14, 475–486.Google Scholar
Wen, Z, Christian, KM, Song, H, Ming, GL (2016). Modeling psychiatric disorders with patient-derived iPSCs. Curr Opin Neurobiol, 36, 118–127.Google Scholar
Wilkinson, ST, Sanacora, G (2019). A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov Today, 24, 606–615.Google Scholar
Willner, P (1984). The validity of animal models of depression. Psychopharmacology, 83, 1–16.Google Scholar
Wong, DF, Tauscher, J, Gründer, G (2008). The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology, 34, 187–203.Google Scholar
Yener, GG, Basar, E (2013). Brain oscillations as biomarkers in neuropsychiatric disorders: following an interactive panel discussion and synopsis. In Basar, E, Basar-Erogu, C, Ozerden, A, Rossini, PM, Yener, GG, eds., Applications of Brain Oscillations in Neuropsychiatric Diseases, Vol. 62. Elsevier, pp. 343–363.Google Scholar
Yuen, ES, Sims, JR (2014). How predictive are photosensitive epilepsy models as proof of principle trials for epilepsy? Seizure, 23(6), 490–493.Google Scholar
Zhang, H, Cohen, AE (2017). Optogenetic approaches to drug discovery in neuroscience and beyond. Trends Biotechnol, 35(7), 625–639.Google Scholar
Zheng, W, Thorne, N, McKew, JC (2013). Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today, 18(21–22), 1067–1073.Google Scholar
Zohar, J, Stahl, S, Moller, HJ, et al. (2015). A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol, 25(12), 2318–2325.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×